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Abstract
Extracellular vesicles (EVs) have recently emerged as
important mediators of intercellular communication. They
are released in the extracellular space by a variety of normal
and cancerous cell types and have been found in all human
body fluids. Cancer-derived EVs have been shown to carry
lipids, proteins, mRNAs, non-coding and structural RNAs
and even extra-chromosomal DNA, which can be taken up
by recipient cells and trigger diverse physiological and
pathological responses. An increasing body of evidence
suggests that cancer-derived EVs mediate paracrine
signalling between cancer cells. This leads to the increased
invasiveness, proliferation rate and chemoresistance, as
well as the acquisition of the cancer stem cell phenotype.
This stimulates angiogenesis and the reprogramming of
normal stromal cells into cancer-promoting cell types.
Furthermore, cancer-derived EVs contribute to the forma‐
tion of the pre-metastatic niche and modulation of anti-
tumour immune response. However, as most of these data
are obtained by in vitro studies, it is not entirely clear which
of these effects are recapitulated in vivo. In the current
review, we summarize studies that assess the tissue
distribution, trafficking, clearance and uptake of cancer-
derived EVs in vivo and discuss the impact they have, both
locally and systemically.
Keywords Extracellular vesicles, biodistribution, traffick‐
ing, tumour microenvironment, immunosuppression,
metastatic niche
1. Introduction
Extracellular vesicles (EVs) are a heterogeneous population
of nanosized membrane vesicles that are released in the
extracellular space by almost all normal and cancer cell
types. Currently, three broad categories of EVs have been
defined. These are based on the mode of biogenesis: (i)
exosomes, (ii) microvesicles and (iii) apoptotic bodies [1].
Exosomes are EVs of endocytic origin, which range from
50-150 nm in diameter. These are released into the extrac‐
ellular environment by a fusion of the multivesicular
bodies (MVBs) with the plasma membrane. Microvesicles
(sometimes also referred to as ectosomes or microparticles)
are large EVs, ranging between 100-1000 nm in diameter,
which are secreted by shedding or budding from the
plasma membrane [2, 3]. Recently, some cancer cells have
been found to secrete very large EVs (1-10 µm) called large
oncosomes. These are due to the shedding of non-apoptotic
plasma membrane blebs, which are characteristic of fast-
migrating “aboeboid” tumour cells [4]. Currently, there is
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no consensus about whether these EVs represent a subclass
of microvesicles or an entirely new class of EVs. Apoptotic
bodies are heterogeneous EVs, which contain cytoplasm
with condensed organelles and/or nuclear fragments. They
are released into the surrounding extracellular space by
apoptotic/dying cells [1]. In vivo, apoptotic bodies are
quickly cleared by macrophages and other phagocytes [5].
Although they have been found to carry miRNAs, which
can be functionally active in the recipient cells [6], they are
structurally and functionally very different from live cell-
derived EVs and will not be discussed in this review.
Although exosomes, microvesicles and oncosomes have
distinct physical and biochemical properties, so far, no
markers that can unambiguously distinguish these types of
EVs have been identified. Furthermore, the current
methods used for the fractionation of EVs cannot reliably
separate various types of EVs [3]. Furthermore, recent
studies have uncovered substantial differences in the EV
biogenesis of various cell types. This suggests that discrim‐
inating these types of EVs could be more complex than
initially thought [3, 7]. Therefore, in the current review, we
will use the term EV to designate all types of live cell-
secreted vesicles.
Cancer-derived EVs have been shown to carry a variety
of  lipids,  proteins,  mRNAs,  non-coding  and  structural
RNAs  and  even  extra-chromosomal  DNA  [8-10].  The
molecular  content  of  EVs  partially  reflects  that  of  the
parent cells. However, studies have shown that they are
enriched in certain molecules, indicating the existence of
specific  mechanisms  that  sort  cargo  into  EVs  [11,  12].
Overall, these mechanisms are poorly understood and are
likely  to  be  related to  the  mode of  EV biogenesis.  The
sorting of specific proteins into EVs can be mediated by
the  endosomal  sorting  complex  for  transport  (ESCRT)
machinery [13] or ESCRT-independent mechanisms such
as tetraspanin [14] or ceramide-dependent pathways [15].
The sorting of  RNAs into EVs can be mediated by the
interaction  of  specific  RNA-binding  proteins,  such  as
hnRNPA2B1,  with  cis-acting  elements  in  the  RNA
sequence [12, 16].
EVs can be taken up by recipient cells and trigger diverse
biological effects. Therefore, they have emerged as impor‐
tant mediators of intercellular communication, both in
normal physiological processes and in the development of
various diseases [8, 9, 17]. In cancer, EVs have been shown
to mediate paracrine signalling between cancer cells, cross-
talk between tumour and microenvironment, contribute to
the formation of the pre-metastatic niche and interfere with
the anti-tumour immune response. However, most of the
data regarding their role in cancer come from in vitro
studies and it is not entirely clear which of the uptake
mechanisms are recapitulated in vivo. Most data are
concerned with the fate of EVs when they are internalized
by various cell types, as well as what mechanisms govern
the trafficking of EVs in the body. In this review, we
summarize studies that aim to assess the tissue distribu‐
tion, trafficking, clearance and uptake of cancer-derived
EVs in vivo. We also discuss the impact that they have been
shown to have, both locally and systemically.
2. Tissue Distribution of Cancer-derived EVs
EVs have been found in various biological fluids, including
blood, milk, urine, saliva, etc. [18]. Here, they represent a
heterogeneous mixture of EVs derived from various cell
types. Several lines of evidence suggest that cancer-derived
EVs can be released into the circulation or other biofluids
of cancer patients. At first, cancer patients have been found
to have higher levels of circulating EVs, compared to
healthy controls [19-21]. Secondly, EVs isolated from the
biofluids of cancer patients or tumour-bearing animals
were shown to contain cancer-associated markers, such as
Melan-A [19], TYRP2 [22] and CA19-9 [23], and amplified
or mutated oncogenes [9, 24]. However, until recently, very
little was known about the half-life, clearance, trafficking
and tissue distribution of cancer-derived EVs in the body.
Data from in vivo studies that address these issues have
only started to accumulate over the last few years. The main
findings of these studies are summarized in Table 1.
In these studies,  two different  approaches for  studying
the  biodistribution  of  EVs  have  been exploited.  One  is
based on administering exogenous EVs into the circula‐
tion of experimental animals, while the other is based on
tumour models that  produce labelled EVs endogenous‐
ly. Most of the studies that used exogenously produced
EVs  isolated  them  from  a  cell  culture  medium  by
differential  ultracentrifugation  and  sucrose  gradient,  as
described  by  Thery  et  al.  2006  [25].  After  the  intrave‐
nous  administration  has  been  conducted,  the  EVs  are
tracked in vivo. This is carried out either by labelling the
EVs with fluorescent membrane dyes, such as DiI, PKH67
and PKH26 [22, 26-32], and loading them with superpar‐
amagnetic iron nanoparticles (SPION5), allowing magnet‐
ic resonance tracking [33]; or by using EVs engineered to
display a membrane reporter [27, 30, 34].
EV reporter systems have been created by the genetic
engineering of cell lines that produce EVs with membrane-
anchored Gaussia luciferase (gLuc), biotin acceptor peptide
(BAP) [27] or green fluorescent protein (GFP) [34]. Studies
that are based on endogenously produced EVs have used
either genetically engineered cancer cell lines, which
produced GFP-tagged CD63 [34, 35], or human cancer
xenografts in mice, where cancer-derived EVs were located
by detecting human CD63 [32]. The EV detection methods
vary depending on the method of EV labelling and the
specific aim of each study. In vivo imaging system (IVIS) is
the method of choice for the analysis of EV tissue distribu‐
tion. However, studies that focus on the specific effects
caused by cancer-derived EVs in specific organs also used
flow cytometry, microscopy, immunohistochemistry, gLuc
activity measurements, magnetic resonance, etc.
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Cell Line Animal Line EV Labelling Injection Site Detection Method Results Ref.
Exogenously Administered EVs into Cancer-free Animals
TS/A murine mammary
tumour
BALB/c PKH67 i.v. Flow cytometry EVs are taken up by bone marrow CD11b
+Gr-1+ cells; suppress myeloid cell
differentiation into DCs.
[26]
EL-4 mouse lymphoma C57BL/6 IRDye800 i.p. LI-COR imager EVs detected in the liver, lung, kidney and




C57BL/6 gLuc-lactadherin i.v. via tail vein gLuc activity
measurement
Half-life of EVs in the blood is ~2 minutes
At 10 to 60 minutes after injection, EVs are
distributed mainly to the liver and lungs;
at 4 hours – lungs and spleen.
[30]
BALB/c gLuc- lactadherin i.v. via tail vein LAS3000 IVIS
C57BL/6 PKH26 i.v. via tail vein Fluorescent microscopy
HEK293T human
embryonic kidney
Athymic nude mice gLuc i.v. via retro-orbital
vein
Bioluminescence imaging 30 minutes after injection, EVs are
distributed to the spleen, liver, lungs and
kidneys; actively taken up by liver and
lung cells but not spleen cells. EVs are




i.v. via tail vein FMT imaging
B16-F10 mouse
melanoma





Nude mice DiI i.v. via tail vein Flow cytometry, IF EVs are internalized by macrophages in the





SD rats n.a. i.v. via tail vein n.a. EVs deliver hybrid BCR/ABL DNA to
normal neutrophils; administration of EVs
induce CML phenotype in mice and rats.
[36]
NOD/SCID mice i.v. via tail vein n.a.




BDX rats n.a. Footpad – first EVs,
then cells
n.a. EVs from metastatic cells support the
metastatic spread of non-metastatic cells to







DiR Footpad IVIS EVs home to sentinel lymph nodes and
enhance migration of melanoma cells to







PKH67 i.v. Confocal microscopy EVs home to the lungs, bone marrow, liver
and spleen. EVs enhance metastasis by
bone marrow education via the transfer of







DiR i.v. via tail vein IVIS EGFR-targeted EVs home to tumour
microenvironment and can deliver








gLuc i.v. via tail vein Bioluminescence imaging Similar amounts of EVs are found in






DiR i.v., i.t. IVIS200 EVs are taken up in the liver and spleen,
very little amounts travel to the tumour.
Slower uptake and clearance in mice with
impaired innate immunity.
Intratumourally administered EVs stay
associated with tumour.
[38]














CD63-GFP n.a. CLSM imaging Breast cancer cells secrete EVs in the
primary and metastatic tumour
microenvironment and blood circulation;
EVs are taken up by cancer cells and CAFs.
[34]
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Human CD63 n.a. IHC EVs are taken up by macrophages in the
lung, brain and lymph nodes; induce
inflammatory processes in tumour
microenvironment and axillary lymph
nodes.*
[32]




Human cancer-derived EVs carry mRNAs
and are detectable in the blood and saliva.
[35]
gLuc – Gaussia luciferase; FMT – fluorescence mediated tomography; i.v. – intravenous; i.p. – intraperitoneal; EV – extracellular vesicle; DC – dendritic cell; BM – bone
marrow; MDMC – monocyte derived myeloid cell; IVIS – In Vivo imaging system; SPION5 – super paramagnetic iron oxide nanoparticles; MRI – magnetic resonance
imaging; PLN – Poplietal lymph node; IF – immunofluorescence; CLSM – confocal laser scanning microscopy; IHC – immunohistochemistry.
Table 1. Studies investigating EV biodistribution and functions in vivo
In cancer-free animals, exogenously administered cancer-
derived EVs were distributed mainly to the liver, lungs,
kidneys and spleen [28, 30] and were also detected in the
lymph nodes [29, 33] and bone marrow [22, 26]. EVs
derived from human embryonic kidney cells (HEK293T)
were predominantly localized in the spleen, followed by
the liver, lungs and kidneys. Additionally, lower amounts
of EVs were also detected in the brain, heart and muscle
[27]. However, when the EV-injected animals were trans‐
cardially perfused with PBS before collecting the organs,
the highest amount of EVs was detected in the kidneys and
not the spleen, followed by the liver and lungs. This
suggests that EVs are actively taken up by the kidney, liver
and lung cells but not the spleen cells. It also indicates that
the accumulation of EVs in the nonperfused spleen may be
due to the uptake of EVs by circulating lymphocytes and
macrophages [27]. In the liver and lungs, they are likely to
be taken up and degraded by phagocytic cells such as
Kuppfer cells and alveolar macrophages [27]. However, a
portion of the EVs may also be internalized by the kidney
cells and released into the urine [27]. A recent study by Cai
et al. (2014) demonstrated that, when injected in rats
eliciting some characteristics of CML, EVs derived from the
CML cell line K562 transferred BCR-ABL hybrid gene to
normal neutrophils. This suggests that EV-mediated
transfer of oncogenes may represent a novel mechanism of
tumourigenesis [36].
Considering that cancer patients have substantially higher
levels of EVs in the blood than healthy individuals [19-21]
and that cell-free RNAs, part of which are likely to be
packaged into EVs, are remarkably stable in the patients’
blood [39], it seemed plausible that EVs should be very
stable in the biofluids. Unexpectedly, when injected in the
blood circulation of immunocompetent mice, murine
melanoma-derived EVs had a half-life of only approxi‐
mately two minutes. Furthermore, they were cleared from
the circulation within four hours [30]. Similarly, when
injected into athymic nude mice [27], HEK293T-derived
EVs had a half-life of less than 30 minutes in vivo in most
tissues. Moreover, lymphoma-derived EVs were taken up
by CD11b+Gr-1+ cells within one hour after the injection into
immunocompetent mice [28]. Such a short half-life of
exogenously administrated EVs was very surprising and
has to be taken into account when designing studies for the
identification of EV-associated cancer biomarkers.
In tumour-bearing animals, both the exogenously admin‐
istered EVs and endogenously produced EVs have also
been found to accommodate the tumour microenviron‐
ment, lymph nodes and bone marrow. However, in such
studies, the largest part of intravenously administered EVs
was rapidly cleared from the circulation. Exogenously
administered HEK293T-derived EVs accumulated in
xenograft tumours at similar levels than the liver and
spleen at 60 minutes post-injection [27]. Nevertheless, it
remained unclear which cell types bind or internalize the
EVs. Several other studies suggest that, in the tumour
microenvironment, cancer-derived EVs can be internalized
by other cancer cells, as well as by surrounding cells like
cancer-associated fibroblasts (CAFs), endothelial cells and
other stroma cells [31, 34, 40]. A number of studies have
demonstrated that cancer-derived EVs are released into the
blood circulation and are trafficked to the lymph nodes,
bone marrow and lungs. Here, they promote metastatic
niche formation and enhance the metastatic spread of
cancer cells to these organs [22, 29, 34, 37]. Furthermore,
when taken up by macrophages, cancer-derived EVs were
shown to induce an inflammatory response [32]. Taken
together, these studies provide a solid basis for the concept
that cancer-derived EVs promote cancer development and
progression in vivo by inducing various biological effects,
both locally and systemically.
3. Uptake of EVs in Tumour Microenvironment
It has become clear that, within the tumour microenviron‐
ment, the cellular composition is complex. Furthermore,
relationships  between  different  cell  types  are  no  less
sophisticated  than  those  in  any  healthy  organs  [41].
Therefore, the role of intercellular communication in the
acquisition  of  various  cancer  phenotypes,  invasive
growth and metastasis and drug resistance is increasing‐
ly recognized.  It  can be mediated by soluble signalling
molecules,  cell-cell  or  cell-matrix  adhesion,  gap  junc‐
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tions  and  EVs  [42].  In  the  tumour  microenvironment,
cancer-derived EVs have been shown to be taken up by
other cancer cells and stromal cells,  such as fibroblasts,
as  well  as  endothelial  cells  and  tumour-infiltrated
immune cells. EVs can exert their effects in the recipient
cells  either  by  binding  to  the  cell  surface  receptors  or
delivering their content inside the recipient cell. Contra‐
ry to the single-molecule signals, EVs have the potential
to affect multiple signalling pathways inside the recipi‐
ent  cell.  Hence,  they  provide  more  efficient  means  for
phenotypic  reprogramming  or  synchronizing  the
physiological  state  of  the  surrounding  cells  [43,  44].
Internalization can occur either through a fusion with the
cell  membrane  [45],  endocytosis  and  micropinocytosis
[46,  47]  or  phagocytosis  [48].  However,  it  is  not  yet
entirely  clear  which  of  these  mechanisms  lead  to  the
degradation  of  EV  components  and  which,  eventually,
result  in  the  release  of  EV content  into  the  cytoplasm.
Here,  it  can  alter  the  physiological  functions  of  the
recipient cell. The recipient cell specificity is likely to be
determined  by  the  composition  of  adhesion  molecules
and lipid content on the surface of EVs and the respec‐
tive ligands on the cellular surface [49-53]. For example,
the  internalization  of  glioblastoma-derived  EVs  was
found  to  depend  on  the  expression  of  heparan  sulfate
proteoglycans on the recipient cells [50]. Meanwhile, the
uptake of rat tumour-derived EVs by specific cell types
depended on the expression of  tetraspanin Tspan8 and
integrin α4 on the EVs [54]. Interestingly, low extracellu‐
lar  pH  (pH  6.0)  has  also  been  shown  to  increase  the
release and uptake of melanoma-derived EVs [45].  This
finding is  particularly significant for understanding the
EV function in the tumour microenvironment, as hypoxia
and extracellular acidosis are common features of the vast
majority of solid cancers. Extracellular acidosis arises by
switching  metabolism  to  glycolysis,  resulting  in  the
increased  production  and  excretion  of  acidic  metabo‐
lites, such as lactic and carbonic acids, and can be as low
as  5.9  [55].  Recently,  low  pH-dependent  EV-mediated
elimination  of  cisplatin  was  also  shown  to  serve  as  a
mechanism of chemoresistance to cisplatin [56].
4. Paracrine Effects Caused by Cancer-derived EVs in the
Tumour Microenvironment
4.1 Cancer Cell Cross-talk
The uptake of cancer-derived EVs by other cancer cells can
lead to increased invasiveness and metastatic potential
[57-60], anchorage-independent growth [24, 61], prolifera‐
tion and chemoresistance [60, 62, 63], as well as inducing
the epithelial-mesenchymal transition (EMT) [59, 64]
(Figure 1). Moreover, cancer-derived EVs are shown to
drive the oncogenic conversion of non-tumourigenic cells
[65, 66]. These effects can be mediated by the transfer of
functionally active proteins, such as HIF1α [59], EGFRvIII
[67], miRNAs [61, 63] and possibly, other non-coding
RNAs, mRNAs and fragments of genomic DNA carrying
various cancer genes and transposable elements [9, 68, 69].
In 1980, Poste and Nicolson provided the first experimental
evidence that EVs, shed from highly metastatic melanoma
cells, could increase the metastatic potential of poorly
metastatic melanoma cells [57]. Later on, several independ‐
ent studies confirmed these findings in vitro and in vivo. A
study by Hao et al. (2006) demonstrated that, when i.v. was
injected into C57BL/6 mice, the EVs released from highly
metastatic melanoma cell line were taken up by poorly
metastatic cells, which acquired the capacity to form
metastatic colonies in the lungs. Similarly, EVs derived
from highly invasive (but not from non-invasive) triple-
negative breast cancer cells significantly increased the
proliferation, migration and invasion capacity of other
breast cancer cell lines [60]. In line with this, EVs from
prostate cancer (PC) patients’ sera have been found to
enhance the proliferation and invasion of PC cell lines [62].
A study by Aga et al. (2014) demonstrated that EVs derived
from EBV-infected nasopharyngeal carcinoma contained
the functionally active transcription factor, HIF1α. Further‐
more, the uptake of HIF1α-containing EVs (but not EVs
containing mutant HIF1α) resulted in the downregulation
of E-cadherin and upregulation of N-cadherin in recipient
cells [59]. Changes in E- and N-cadherin expression are
markers for EMT that confer mesenchymal properties to
epithelial cells. This is associated with invasion and
metastasis, as well as the acquisition of cancer stem cell
phenotype [70]. Furthermore, EVs from drug-resistant cell
line variants have been shown to confer resistance to non-
resistant PC or breast cancer cells [62, 63].
Al-Nedawi et al. (2008) demonstrated that glioma cells with
a mutated form of epidermal growth factor receptor
(EGFRvIII) release it via EVs, which were taken up by
indolent glioma cells [24]. This resulted in the activation of
MAPK and Akt signalling pathways. It also led to changes
in the expression of EGFRvIII-regulated genes, resulting in
the morphological transformation and increase in anchor‐
age-independent growth capacity [24]. Furthermore, breast
and colorectal cancer (CRC) cells have been shown to
release Amphiregulin (AREG), an EGFR ligand, via EVs
[71]. When taken up by breast cancer cells, EV-packaged
AREG displayed greater membrane stability and increased
invasiveness. Interestingly, the AREG level in EVs corre‐
lated with the mutant KRAS status of the donor cells [71].
Later on, the same group demonstrated that mutant KRAS
status affects the composition of the EV proteome. When
taken up by CRC cells with wt KRAS, EVs derived from
CRC cells with mutated KRAS contained many tumour-
promoting proteins, including KRAS and EGFR, and
enhanced colony formation [72]. Another study demon‐
strated that EVs derived from a hepatocellular carcinoma
(HCC) were enriched in specific miRNAs that could be
taken up by other HCC cells. This resulted in the modula‐
tion of TAK1 signalling pathway and enhanced anchorage-
independent growth [61].
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A recent study by Melo et al. (2014) highlights a novel
mechanism that could potentially impact our understand‐
ing of the physiological role of cancer-derived EVs. This
study demonstrated that, in contrast to those produced by
normal cells, breast cancer EVs bear a RISC-loading
complex. This is associated with pre-miRNAs that are
capable of cell-independent miRNA biogenesis. These EVs
were able to mediate the rapid and efficient silencing of
target mRNAs of recipient cells and, importantly, were
shown to have a protumourigenic effect on non-tumouri‐
genic epithelial cells. It was demonstrated that the impact
was dependent on the presence of Dicer within cancer EVs
[65]. The authors proposed that cancer EVs are capable of
inducing an oncogenic “field effect” by subjugating
neighbouring normal cells to cooperate in cancer progres‐
sion. In addition, another excellent study by Abd Elmageed
et al. (2014) showed, for the first time, that EVs produced
by prostate cancer cells are capable of inducing a neoplastic
transformation of tumour-trophic mesenchymal stem cells.
The EV-primed adipose-derived tissue stem cells under‐
went a mesenchymal-to-epithelial transition, adopted
genetic instability and oncogenic transformation, and were
able to form tumours in vivo. This was achieved through
the oncogenic factor transfer by prostate cancer cell-
derived EVs, which included oncogenic miRNAs, K-ras
and H-ras transcripts and oncoproteins [66].
Figure 1. Local and systemic effects that are triggered by cancer-derived EVs. Locally cancer-derived EVs have been reported to promote proliferation,
invasiveness and chemoresistance, and to induce EMT in cancer cells in a paracrine manner, and to stimulate angiogenesis and reprogramming of stromal
cells into CAFs. Systemically, cancer-derived EVs have been shown to contribute to the generation of metastatic microenvironment by reprogramming BMDCs,
regulating gene expression in the lungs and lymph nodes and modulating anti-tumour immune response. BMDCs, bone marrow-derived cells; ECM,
extracellular matrix; EMT, epithelial-mesenchymal transition; CAF, cancer-associated fibroblast; DC, dendritic cells; MDSC, myeloid-derived suppressor cell;
NK, natural killer cell; TCR, T cell receptor.
However, several recent findings have challenged the
paradigm of the pro-tumourigenic role of cancer-derived
EVs, suggesting that cancer-derived EVs can also have
opposite or, so far, unknown roles. For example, a recent
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study by Gabriel et al. (2013) demonstrated that EVs
derived from various cancer cell lines and PC patients’
plasma contained a functionally active tumour-suppressor
protein PTEN that suppressed the proliferation of PTEN-
deficient recipient cells [107]. As the authors did not detect
it in the EVs derived from normal cells and plasma from
healthy individuals, they suggested that this might
represent a mechanism used by cancer cells to downregu‐
late PTEN level [107]. Meanwhile, another study found a
functional PTEN protein in EVs, produced by mouse
embryonic fibroblasts and human embryonic kidney cells
[108]. This suggests that this could be a more wide spread
phenomenon, provoking questions regarding its biological
significance in normal physiological processes and cancer.
Moreover, it remains to be determined which cell types
actively take up PTEN-containing EVs in vivo and whether
they exert the same physiological effects in cancerous and
normal cells.
Taken together, several lines of evidence strongly support
the concept that cancer-derived EVs act paracrinally to
synchronize the physiological state in subpopulations of
cells. They do this by delivering signalling molecules that
are not endogenously expressed in the recipient cells and
thus, driving the cancer progression. Furthermore, they
may even induce the acquisition of cancer cell phenotype
in non-malignant cells. However, various EV subpopula‐
tions differ in their molecular content and may cause
opposite effects in the recipient cells. Thus, further studies
that dissect the heterogeneity of EVs and the recipient cell
selectivity are urgently needed.
4.2 Promotion of Angiogenesis
Cancer-derived EVs have also been shown to promote
angiogenesis. A number of independent studies have
demonstrated that cancer-derived EVs can be taken up by
the endothelial cells in vitro and in vivo. This results in
morphological changes, migration and proliferation of
endothelial cells, tube formation and neovascularization
[40, 67, 73-78]. Apparently, these effects can be mediated by
the transfer of angiogenic proteins [73] and oncogenic
proteins [67], as well as various mRNAs and miRNAs [40,
78, 79]. While the angiogenic proteins, such as angiogenin,
IL-6, IL-8, TIMP-1 and VEGF, are likely to impact in a
paracrine manner, the delivery of oncogenic EGFR to the
endothelial cells was shown to trigger the endogenous
expression of VEGF, followed by the autocrine activation
of VEGF receptor-2 signalling [67]. Several studies empha‐
size the role of EV-shuttled miRNAs in the endothelial cell
migration and neovascularization. A study by Umezu et al.
(2012) demonstrated that the uptake of leukaemia cell-
derived EVs carrying miR-92a enhanced endothelial cell
migration and tube formation [79]. Meanwhile, Zhuang et
al. (2012) showed that tumour-secreted miR-9 triggered the
activation of JAK-STAT pathway in the endothelial cells,
resulting in enhanced migration and tumour angiogenesis
[78]. Furthermore, the administration of anti-miR-9 or JAK
inhibitors suppressed these effects in vitro and in vivo [78].
Likewise, the treatment of mice carrying human carcinoma
xenografts with Diannexin, a drug that binds phosphati‐
dilserine and blocks EV exchange, resulted in the reduction
of tumour growth rate and microvascular density [67].
Collectively, these studies demonstrated, both in vitro and
in  vivo,  that  cancer-derived  EVs  have  a  pro-angiogenic
capacity  and  therefore,  might  represent  an  attractive
target for therapeutic intervention. However,  to date,  it
is not entirely clear at what stages of maturation endothe‐
lial cells are targeted by cancer-derived EVs in vivo.
4.3 Acquisition of CAF Phenotype
Among the different components of the tumour stroma,
cancer-associated fibroblasts (CAFs) are one of the main
elements. CAFs are defined as all the fibroblastic, non-
neoplastic, non-vascular, non-epithelial and non-inflam‐
matory cells with a stable karyotype found in a tumour [80].
CAFs promote tumour progression by secreting soluble
growth factors, cytokines and chemokines that stimulate
proliferation and migration of cancer cells, induce angio‐
genesis, modify tumour metabolism, stimulate acquisition
of cancer stem cell phenotype and modulate the immune
response [80, 81]. CAFs can originate from resident tissue
fibroblasts, mesenchymal stem cells, myofibroblasts and
even epithelial and endothelial cells via EMT or EndMT,
respectively [80]. This process is accompanied by persistent
changes in their gene methylation pattern [82, 83]. Once the
CAF phenotype is acquired, two autocrine signalling loops,
mediated by TGF-β and SDF-1 cytokines, maintain them in
this differentiation state in an autocrine manner [84].
A growing body of evidence suggests that cancer-derived
EVs play a crucial role in the reprogramming of these cells
into CAFs via the transfer of TGFβ. Thus, for instance,
TGFβ1 containing PC-derived EVs was found to be taken
up by primary lung fibroblasts, resulting in their differen‐
tiation into tumour-promoting CAFs [85, 86]. These cells
supported angiogenesis in vitro and tumour growth in
vivo. Interestingly, this effect could not be achieved by
using soluble TGFβ1 and appeared to depend on heparan
sulphate chains on the EV surface. Moreover, EV-deficient
(Rab27a knock-down) cancer cells failed to achieve activa‐
tion of the tumour stroma [86]. Likewise, gastric cancer-
derived EVs were shown to trigger the differentiation of
umbilical cord-derived mesenchymal stem cells into CAFs
by the transfer of TGFβ and the subsequent activation of
TGFβ/Smad pathway [87]. Furthermore, breast cancer-
derived EVs were found to convert adipose tissue-derived
mesenchymal stem cells into CAFs expressing various
tumour-promoting factors [88].
Hence, cancer-derived EVs seem to play a crucial role in the
induction of CAF phenotype via the transfer of TGFβ.
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5. Systemic Effects Caused by Cancer-derived EVs
5.1 Formation of Pre-metastatic Niche
The first evidence that cancer-derived EVs can contribute
to the generation of metastatic microenvironment was
provided by Jung et al. (2009) [37]. In this study, rats
received injections of a conditioned medium containing
EVs and a soluble matrix obtained from highly metastatic
pancreatic cancer cells, followed by the injection of the
respective cancer cells. This showed that the conditioned
medium promoted the settlement of a non-invasive variant
of these cells in the lymph nodes and lungs. This suggested
that highly metastatic cells deliver messages that elicit
alterations in pre-metastatic organs. This allows the
homing, settling and growing of poorly metastatic cells
[37]. Another study demonstrated that, when injected in the
mouse footpad, mouse melanoma-derived EVs, home to
sentinel lymph nodes, enhance the migration of melanoma
cells to the EV-rich sites in the lymph nodes. In the lymph
nodes, EVs were found to regulate the expression of a
variety of genes involved in migration, extracellular matrix
deposition and vascular proliferation [29]. Moreover, EVs
derived from putative renal cancer stem cells were found
to increase the number of lung metastases, when intrave‐
nously injected in SCID mice [74]. An elegant study by
Peinado et al. (2012) demonstrated that, when injected in
mice, EVs derived from highly malignant mouse melano‐
ma, home to the lungs and bone marrow, enhance endo‐
thelial permeability at pre-metastatic sites and promote the
development of distant metastasis. These EVs were found
to “educate” bone marrow-derived cells (BMDCs) by
transferring the MET oncoprotein, resulting in the activa‐
tion of the MET pathway in BMDCs. They become condi‐
tioned to support tumour vasculogenesis, invasion and
metastasis. Furthermore, higher amounts of MET were
found in circulating EVs isolated from patients with stage
three and four melanoma than in healthy controls. This
shows that this finding may also have relevance in a clinical
setting [22].
A number of preclinical studies suggest that cancer-
derived EVs have a systemic effect on the conditioning of
a pre-metastatic niche and hence, set the basis for a new
therapeutic strategy. However, it remains to be determined
whether or not this type of signalling represents a common
mechanism of metastasis in various human cancers.
5.2 Modulation of Anti-tumour Immune Response
Cancer-derived EVs have been reported to both stimulate
and suppress anti-tumour immune responses [11]. They
are shown to contain tumour-associated antigens, such as
CEA and MART1, and are efficiently taken up by dendritic
cells. In turn, these cross-present the antigens to CD8+ T
cells, resulting in potent anti-tumour effects [89, 90].
Moreover, as they bear MHC class I molecules, it has been
suggested that they could directly stimulate CD8+ T cells
[11]. In fact, several pre-clinical and clinical studies based
on the immunization with cancer-derived EVs, in combi‐
nation with various cytokines, have shown the induction
of beneficial tumour-specific CD8+ T cell responses. Such
studies suggest that they may represent an attractive
approach for cancer immunotherapy [91-94].
On the other hand, increasing evidence suggests that
cancer-derived EVs can suppress the anti-tumour immune
response in a variety of ways. For instance, melanoma-
derived EVs have been shown to be enriched for FasL and
induced Fas-mediated apoptosis in T cells [95]. Subsequent
studies have described similar immune evasion mecha‐
nisms, mediated by FasL or TRAIL expression, on EVs in
prostate and colorectal cancer and glioma [96-99]. More‐
over, FasL expression can also lead to the TCR impairment
due to the downregulation of CD3-ζ chain, which has been
reported in ovarian [100, 101] and head and neck squamous
carcinoma patients [98]. Contrary to the effector T cells,
CD4+CD25highTregs are resistant to FasL-induced apoptosis
and cancer-derived EVs have been reported to stimulate
the expansion and suppressive functions of Tregs [98, 102,
103]. Ovarian cancer-derived EVs have been shown to
promote the proliferation of CD4+CD25+FOXP3+T cells,
convert CD4+CD25neg T cells into CD4+CD25+Tregs and
upregulate Treg suppressor functions (e.g., production of
perforin, Granzyme B, IL-10, etc.), when added to the
culture of peripheral blood T cells obtained from healthy
donors [102]. At least partially, this effect seems to be
mediated by EV-transferred TGFβ1. This is because the pre-
treatment of malignant-effusion derived EVs, with neutral‐
izing antibodies against TGFβ1, reduced the expansion and
suppressive functions of Tregs [104]. However, another
recent study demonstrated that CD4+CD25highTreg expan‐
sion and IL-10 secretion is promoted by cancer cell-secreted
miR-214 that targets PTEN in CD4+ T cells [105].
Other EV-mediated immunosuppressive mechanisms
include T cell inhibition via the production of extracellular
adenosine by EV-expressed CD39 and CD73 [106], and the
downregulation of the activating receptor NKG2D on NK
and CD8+ T cells by EV-transferred TGFβ [103, 107].
Cancer-derived EVs have also been shown to suppress the
cytotoxic activity of NK cells by expressing MICA, which
triggers the downregulation of NKG2D from the cell
surface and reduces NK cytotoxicity [108].
In addition, cancer-derived EVs have multiple effects on
myeloid precursors, dendritic cells and macrophages.
Cancer-derived EVs have been shown to block the differ‐
entiation of myeloid precursors into dendritic cells and
promote the generation of myeloid-derived suppressor
cells via Stat3 activation [26, 109, 110]. In turn, this results
in the suppression of effector T cell proliferation, activation
and cytolytic functions and the induction of Treg cells [109,
111]. In macrophages, melanoma and breast cancer-
derived EVs (but not those from non-cancerous cells) have
been reported to activate NF-κB signalling and to alter the
cytokine and chemokine profile, favouring the production
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of pro-inflammatory cytokines. However these changes
were complex and not consistent with M1 or M2 polariza‐
tion [32, 112]. Hence, the role of cancer-derived EVs in the
macrophage-mediated tumour-promoting or anti-tumour
effects is not entirely clear and, presumably, may vary
depending on their content and physiological state of their
cell-of-origin.
6. Concluding Remarks and Future Directions
Collectively,  these  studies  strongly  support  the  para‐
digm of the cancer-promoting role of cancer-derived EVs.
They suggest that inhibition of the formation or uptake
of  cancer-derived  EVs  or  their  components  could  be  a
novel  therapeutic  avenue.  In  fact,  several  studies  have
demonstrated that blocking the production or uptake of
EVs  or  specific  miRNAs  carried  by  EVs  reduced  tu‐
mour  growth  and  angiogenesis.  This  clearly  shows  a
therapeutic benefit [67, 78, 113].
In addition, natural or genetically engineered EVs can be
exploited as tools for delivery of virus-like particles or other
gene therapy products, allowing to evade pre-existing
neutralizing antibodies against the viral vectors and to
increase transduction efficiency [114, 115].
Moreover, cancer-derived EVs seem to have very diverse
effects on immune cells, which may lead to the stimulation
or suppression of anti-tumour immune responses. Hence,
a deeper understanding of mechanisms and how they
impact the functions of various immune cell subsets could
help to develop novel strategies for shifting the balance
towards immunostimulatory tumour microenvironment.
However, it remains unclear whether it is possible to
entirely stop cancer progression by inhibiting the forma‐
tion or uptake of cancer-derived EVs. It seems likely that
cancers differ in their ability to produce EVs and in the
degree to which they depend on the EV-mediated signal‐
ling. However, to the best of our knowledge, the levels of
EVs and their effects have not been systematically studied
during the course of disease progression and compared
among different cancer types. Another layer of complexity
is added by the heterogeneity of EV biogenesis and the
composition of their molecular cargo. Currently, there is
great controversy regarding what types of EVs each cell
type produces and which of them carry molecular cargo
that are capable of eliciting biologically significant effects.
For instance, many studies have reported that exosomes are
enriched in miRNAs, suggesting that they function as
vehicles for the intercellular transfer of miRNAs [8,
116-120]. Nonetheless, a recent study by Chevillet et al.
(2014) has challenged this view by demonstrating that, on
average, most exosomes harbour less than one molecule of
a given miRNA. However, it remains unclear whether rare
exosomes in the population carry many copies of a given
miRNA or whether a larger fraction of exosomes carries a
low concentration of miRNAs [121]. In this regard, a recent
study by Thakur et al. (2014) demonstrated that exosomes
carry dsDNA representing the whole genomic DNA.
However, only a subset (~10%) of exosomes contained
DNA [122]. Hence, the characterization of EV subpopula‐
tions carrying cancer-derived molecular cargo seems to be
of paramount importance for designing studies aimed at
the discovery of EV-associated biomarkers and therapeutic
targeting of EVs.
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